Dear Mr. Kramer:

Please refer to your supplemental new drug application dated 30 September 2005, received 3 October 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Cozaar (losartan potassium) 25, 50, and 100 mg Tablets.

This “Changes Being Effected in 30 days” supplemental new drug application provides for:

1. Under Precautions-Drug Interaction section, the following third paragraph was deleted:

   As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug indomethacin.

   The following paragraphs were added:

   **Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors:** In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs (NSAIDS) including those that selectively inhibit cyclooxygenase-2 inhibitors (COX-2 inhibitors), the co-administration of angiotensin II receptor antagonists including losartan, may result in a further deterioration of renal function. These effects are usually reversible.

   Reports suggest that NSAIDS including selective COX-2 inhibitors may diminish the antihypertensive effect of angiotensin II receptor antagonists, including losartan. This interaction should be given consideration in patients taking NSAIDS including selective COX-2 inhibitors concomitantly with angiotensin II antagonists.

2. Under DOSAGE AND ADMINISTRATION, *Pediatric Hypertensive Patients ≥6 years of age;* the last sentence in this subsection now reads as follows:

   *See CLINICAL PHARMACOLOGY, Pharmacokinetics, Special Populations, Pharmacodynamics, and Clinical Effects, and WARNINGS, Hypotension – Volume Depleted Patients.*
3. Under HOW SUPPLIED, the following were added:
   a. NDC-006-0951-87 Bottles of 10,000
   b. NDC-006-0952-87 Bottles of 10,000
   c. NDC-006-0960-86 Bottles of 5,000

4. Minor editorial revisions were noted:
   a. Label component number was revised from 9573528 to 9573530
   b. Comma replaced colon after “See WARNINGS” in Box Warning
   c. Issue date updated to April 2005
   d. Copyright date updated to 2003

We completed our review of this supplemental new drug application. It is approved, effective on the
date of this letter, for use as recommended in the electronic final printed labeling (eFPL) submitted on
30 September 2005.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health
Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to
the following address:

MEDWATCH
Food and Drug Administration
WO 22, Room 4447
10903 New Hampshire Avenue
Silver Spring, MD 20993-0002

We remind you that you must comply with the requirements for an approved NDA set forth under
21 CFR 314.80 and 314.81.

If you have any questions, please call:

Cheryl Ann Borden, MSN, RN, CCRN, CCNS
Regulatory Health Project Manager
(301) 796.1046.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Drug
Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

---------------------
Norman Stockbridge
3/31/2006 08:57:26 AM